Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 35 of 35 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	predicted - resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	sensitive	Lorlatinib	Lorlatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910; NCT01970865).	26698910
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	no benefit		Luminespib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	conflicting		Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	conflicting		Ceritinib	Case Reports/Case Series	Actionable	In a Phase I trial, Zykadia (ceritinib) treatment resulted in a partial response in a patient with non-small cell lung cancer harboring EML4-ALK (e18:e20) and ALK C1156Y (PMID: 34890832; NCT01283516).	34890832
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	conflicting		Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).	24675041
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 24887559).	24887559
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		TQ-B3139	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TQ-B3139 (CT-711) inhibited proliferation of cells expressing EML4-ALK with ALK C1156Y in culture and inhibited tumor growth in a cell line xenograft model (PMID: 30210922).	30210922
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408).	21613408
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).	21575866
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity (PMID: 26939704).	26939704
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	predicted - sensitive		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	predicted - sensitive		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing ALK C1156Y in the context of EML4-ALK demonstrated minimal sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		Iruplinalkib	Preclinical - Cell culture	Actionable	In a preclinical study, Iruplinalkib (WX-0593) inhibited growth of transformed cells expressing ALK C1156Y in the context of EML4-ALK in culture (PMID: 35421578).	35421578
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	predicted - sensitive		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y demonstrated moderate resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	predicted - sensitive		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		XMU-MP-5	Preclinical - Cell culture	Actionable	In a preclinical study, XMU-MP-5 treatment decreased downstream signaling and inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 34845836).	34845836
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Ensartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ensacove (ensartinib) inhibited viability of a cell line expressing EML4-ALK with ALK C1156Y in culture (PMID: 31446141).	31446141
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of a cell line expressing EML4-ALK with ALK C1156Y in culture (PMID: 31446141).	31446141
EML4 - ALK ALK C1156Y	lung non-small cell carcinoma	sensitive		Afatinib + Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Gilotrif (afatinib) and Lorbrena (lorlatinib) further inhibited viability of a patient-derived non-small cell lung cancer cell line harboring EML4-ALK (e6:e19) with ALK C1156Y compared to Lorbrena (lorlatinib) alone in culture (PMID: 37748191).	37748191
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 inhibited viability of cells expressing EML4-ALK and ALK C1156Y in culture (PMID: 39269178).	39269178
EML4 - ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensacove (ensartinib) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).	21613408

Showing 1 to 35 of 35 entries

Filter rows:

Profile Name	EML4 - ALK ALK C1156Y
Gene Variant Detail	ALK C1156Y (unknown) EML4 - ALK (gain of function)
Relevant Treatment Approaches	Alectinib Brigatinib Ensartinib Lorlatinib

We’re improving your experience!

Molecular Profile Detail

Contact

Filtering

Sorting